Combined Screening (Immulite)

Combined Screening (Immulite)

Overview

Combined Screening (Immulite) is a prenatal screening test performed during the first trimester of pregnancy to assess the risk of certain chromosomal abnormalities in the fetus. The test measures specific maternal serum markers using the Immulite immunoassay platform and is interpreted along with ultrasound findings and maternal age.

Test Components

• Pregnancy-Associated Plasma Protein A (PAPP-A)
• Free Beta Human Chorionic Gonadotropin (Free β-hCG)
• Nuchal Translucency (NT) scan findings
• Maternal age and clinical details

Why This Test Is Done

• Screens for risk of Down syndrome (Trisomy 21)
• Screens for risk of Edwards syndrome (Trisomy 18)
• Helps identify pregnancies requiring further diagnostic evaluation
• Supports early prenatal risk assessment

Sample Required

• Maternal blood (Serum)

Preparation

• No fasting is generally required.
• Accurate gestational age and NT scan details should be provided.

Benefits

• Non-invasive prenatal screening
• Early risk assessment during pregnancy
• Helps guide further diagnostic decisions
• Provides valuable information for prenatal care planning

Recommended For

• Pregnant women between 11 and 13 weeks + 6 days of gestation
• Women seeking first-trimester chromosomal abnormality screening
• Pregnancies with increased maternal age or family history concerns

Interpretation

Results are reported as a calculated risk estimate and not as a definitive diagnosis. High-risk results may require additional testing such as non-invasive prenatal testing (NIPT) or diagnostic procedures as advised by the healthcare provider.

Keywords

Combined Screening Test, First Trimester Screening, Immulite Screening, PAPP-A Test, Free Beta hCG, Down Syndrome Screening, Trisomy 21 Screening, Prenatal Screening Test, Maternal Serum Screening, Pregnancy Risk Assessment